Videos

How Cancer Care Teams Can Help With the Cessation of Smoking

May 8th 2025, 8:00pm

Video

Dr. Daniel J. Boffa shared how cancer care teams support patients in quitting smoking and how new data may guide improvements in high-smoking U.S. regions.

Managing Elacestrant Treatment: From Patient Selection to Supportive Care

May 8th 2025, 12:05pm

Video

Panelists discuss balancing clinical trial data with real-world patient factors when choosing between treatment options, emphasizing the importance of quality of life alongside cancer control in the second-line setting.

EMERALD Trial Results: What Prior CDK4/6i Duration Means for Treatment Success

May 8th 2025, 12:00pm

Video

Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its FDA approval for this specific population.

Immune Therapy Expands Melanoma Treatment to More Patients

May 6th 2025, 8:00pm

Video

Immune therapy is generally safer than chemotherapy, allowing more patients with melanoma and other conditions like heart or lung issues receive treatment.

A Personalized Approach to Bladder Preservation in Urologic Cancers

May 5th 2025, 8:00pm

Video

Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment plan.

Mitigating Peripheral Neuropathy During Cancer Treatment

May 5th 2025, 7:00pm

Video

Dr. Shirley D'Sa discusses the importance of catching peripheral neuropathy in patients with Waldenström macroglobulinemia early on and how to treat it.

Exploring a Patient Case: Biomarker Testing After Progression and Discussing Treatment Choices With Your Care Team

May 5th 2025, 3:04pm

Video

Panelists discuss how to communicate genomic testing results to patients and make shared treatment decisions, particularly when multiple targeted therapy options are available for patients with ESR1 and PIK3CA mutations.

Navigating Treatment After Progression: Testing, ESR1 Mutations and Tolerable Options

May 5th 2025, 3:00pm

Video

Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering patient-specific factors.

Dr. Eng Breaks Down Braftovi Plus Erbitux FDA Approval in BRAF+ mCRC

May 3rd 2025, 6:00pm

Video

Dr. Cathy Eng discusses the importance of the Braftovi plus Erbitux FDA approval for treatment-naive BRAF V600E+ metastatic colorectal cancer.

Breaking Down the Benefits of Clinical Trial Participation in Cancer Care

May 2nd 2025, 8:00pm

Video

Dr. Scott T. Tagawa discusses what patients with prostate cancer should know about the potential benefits and risks of participating in a clinical trial.